TCNO Bioscience, an innovative anticancer drug development company, announced on the 27th that it received a commendation from the Minister of Health and Welfare at the 2025 Health Industry Promotion and Healthcare Technology Commercialization Awards in recognition of its achievements in developing the innate immune anticancer drug TXN10128 (ENPP1 inhibitor).
This award is hosted by the Ministry of Health and Welfare and organized by the Korea Health Industry Development Institute. It is a system to discover and encourage those who have contributed to startups and technology commercialization in the healthcare field.
TXN10128, currently under development by Ticino Biosciences, is a member of the ENPP1 inhibitor family that has entered Phase 1 clinical trials and has secured initial proof-of-concept (human POC) in patients. Furthermore, its technological potential has been recognized by the U.S. Food and Drug Administration (FDA), receiving orphan drug designation for pancreatic cancer. The company is developing TXN10128 as the world's first innate immune anticancer drug.
CEO Park Chan-sun stated that this award will serve as a significant catalyst for strengthening the company's global competitiveness and pledged to continue developing innovative new drugs to contribute to patients and society. The company plans to accelerate clinical development of its key pipeline and preparations for a technology-specific listing.
- See more related articles
You must be logged in to post a comment.